Table 2.
Variables analyzed.
| Variables included in the analysis | % (N); Mean ± SD (Median) |
|---|---|
| Age | 71.4 ± 11.4 (72.5) |
| Baseline NIHSS | 17.6 ± 4.3 (17.5) |
| History of HTN | 56% (71/127) |
| A-fib | 40% (51/127) |
| Smoker | 32% (40/126) |
| DM | 14% (128/127) |
| Baseline ASPECTS | 7.0 ± 1.8 (7.0) |
| Infarct growth (ml) | 45.6 ± 85.3 (14.7) |
| Time to groin (min) | 193.9 ± 71.7 (180.0) |
| Propofol dose (mg) | 249.3 ± 214.9 (213.0) |
| Phenylephrine % used; dose | 77% (99/128) |
| ETCO2 (kPa) | 4.5 ± 0.4 (4.5) |
| MAP < 70 mmHg | 26% (33/128) |
| Ephedrine % used; dose | 38% (48/128) |
| Evaluable collaterals | 62% (80/128) |
| M1 | 83% (44/53) |
| Tandem (ICA/M1) | 31% (9/29) |
| ICA T | 32% (6/19) |
| ICA neck | 50% (4/8) |
| M2 | 47% (9/19) |
| Modified ASITN grade | |
| 1 | 11% (9/80) |
| 2− | 24% (19/80) |
| 2+ | 39% (31/80) |
| 3 | 26% (21/80) |
| 4 | 0 |